The earnings call highlighted significant progress in Xenon's late-stage and early-stage clinical programs, particularly for azetukalner in epilepsy and neuropsychiatric disorders. Financially, the company is well-positioned to support its operations and pipeline development. While challenges exist, such as increased competition and screening hurdles, the positive advancements and robust financial health contribute to an overall optimistic outlook.

Company Guidance

In the recent Xenon Pharmaceuticals earnings call, the company provided extensive guidance on their ongoing clinical programs and financial outlook. Xenon highlighted three strategic priorities, including the Phase III X-TOLE2 study of azetukalner for focal onset seizures, with top-line data expected in early 2026. They have successfully randomized 380 patients, exceeding their target of 360, enhancing the study's power. The company is also exploring azetukalner's potential in neuropsychiatric conditions, with Phase III trials in major depressive disorder (MDD) and bipolar depression. Xenon anticipates having sufficient cash to fund operations into 2027, bolstered by a strong balance sheet of $555.3 million as of September 2025. They also discussed early-stage programs, including Nav1.7 and Kv7 ion channel modulators, which are now in Phase I trials. Xenon plans to leverage its ion channel expertise to develop innovative treatments across multiple therapeutic areas.

Phase III X-TOLE2 Study Completion

The X-TOLE2 study for azetukalner in focal onset seizures successfully completed patient randomization with 380 patients, exceeding the initial target of 360, ensuring robust power across study endpoints.

Progress in Neuropsychiatric Indications

Xenon has made significant progress with the X-NOVA2 and X-NOVA3 trials in major depressive disorder (MDD) and the X-CEED trial in bipolar depression, demonstrating potential for azetukalner beyond epilepsy.

Strong Financial Position

Cash, cash equivalents, and marketable securities totaled $555.3 million as of September 30, 2025, providing sufficient funds to support operations into 2027.

Expansion of Early-Stage Pipeline

Xenon advanced its early-stage Nav1.7 and Kv7 pain programs, XEN1701 and XEN1120, into Phase I studies, and plans to initiate Phase II proof-of-concept studies next year.

Xenon (XENE) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

XENE Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Feb 26, 2026	2025 (Q4)	-1.19 / -	-0.84	―	―	―
Nov 03, 2025	2025 (Q3)	-1.15 / -1.15	-0.81	-41.98% (-0.34)	―
Aug 11, 2025	2025 (Q2)	-0.99 / -1.07	-0.75	-42.67% (-0.32)	―
May 12, 2025	2025 (Q1)	-0.90 / -0.83	-0.62	-33.87% (-0.21)	―
Feb 27, 2025	2024 (Q4)	-0.86 / -0.84	-0.64	-31.25% (-0.20)	―
Nov 12, 2024	2024 (Q3)	-0.82 / -0.81	-0.73	-10.96% (-0.08)	―
Aug 08, 2024	2024 (Q2)	-0.70 / -0.75	-0.72	-4.17% (-0.03)	―
May 09, 2024	2024 (Q1)	-0.66 / -0.62	-0.63	1.59% (+0.01)	―
Feb 29, 2024	2023 (Q4)	-0.76 / -0.64	-0.57	-12.28% (-0.07)	―
Nov 08, 2023	2023 (Q3)	-0.77 / -0.73	-0.57	-28.07% (-0.16)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

XENE Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 03, 2025	$41.12	$39.09	-4.94%
Aug 11, 2025	$34.11	$35.99	+5.51%
May 12, 2025	$35.85	$29.60	-17.43%
Feb 27, 2025	$38.31	$37.02	-3.37%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Xenon (XENE) report earnings?

Xenon (XENE) is schdueled to report earning on Feb 26, 2026, After Close (Confirmed).

What is Xenon (XENE) earnings time?

Xenon (XENE) earnings time is at Feb 26, 2026, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is XENE EPS forecast?

XENE EPS forecast for the fiscal quarter 2025 (Q4) is -1.19.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing